Perspective

iMedPub Journals
www.imedpub.com

Pharmaceutical Biotechnology: Current Research

2025
Vol.9 No.1:167

Utilizing Nanotechnology to Boost Drug Absorption Rates

Pingye Jin*

Department of Medicinal Chemistry, Mazandaran University of Medical Sciences, Sari, Iran

***Corresponding author:** Pingye Jin, Department of Medicinal Chemistry, Mazandaran University of Medical Sciences, Sari, Iran; E-mail: Pingye@gmail.com

Received date: December 27, 2023, Manuscript No. IPPBCR-24-18324; **Editor assigned date:** December 30, 2023, PreQC No. IPPBCR-24-18324 (PQ); **Reviewed date:** January 16, 2024, QC No. IPPBCR-24-18324; **Revised date:** February 19, 2025, Manuscript No. IPPBCR-24-18324 (R); **Published date:** February 26, 2025, DOI: 10.36648/ippbcr.9.1.167

Citation: Jin P (2025) Utilizing Nanotechnology to Boost Drug Absorption Rates. Pharm Biotechnol Curr Res Vol:9 No:1

Introduction

Patients with advanced or metastatic renal cell carcinoma should start with pazopanib. Be that as it may, the financially accessible planning is portrayed by low solvency, unfortunate bioavailability and sub-standard restorative fixations in greater part of patients. A Self-Microemulsifying Drug Delivery System (SMEDDS) for pazopanib with improved solubility and a faster dissolution rate than the pure drug and the commercial formulation was the goal of this study.

Description

Based on a solubility study, capmul MCM C8, Tween 20, and propylene glycol were chosen for the composition of SMEDDS. In the ACHN cell line, the optimized SMEDDS was 2-3 times more cytotoxic than the pure drug. According to these findings, the marketed formulation of pazopanib SMEDDS possessed enhanced cytotoxic potential and improved solubility and dissolution rate in comparison to the pure drug.

One of the promising applications of nanotechnology for the effective delivery of drugs to the intended location is the nanoparticle delivery system. Be that as it may, the choice of lead excipient, guess of miscibility/dissolvability boundaries, drug stacking capacity, drug discharge rate, steadiness expectation, and the transportation of nanoparticles through a mind boggling organization of veins, drug-target acknowledgment, and restricting are a portion of the urgent perspectives for nanoparticle detailing improvement. Computational fluid dynamics simulations, dissipative particle dynamics simulations, coarse-grained molecular dynamics modelling, quantum mechanical simulation techniques, atomistic molecular dynamics, quantitative structure–activity relationships, discrete element modelling, and physiologically based pharmacokinetic modelling are just a few of the molecular computational models that can be The ongoing audit centres around the computational reproduction displaying apparatuses used to create nanoparticle definitions and their importance in planning different natural and inorganic Nano platforms utilized in drug conveyance.

To capture the value of massive multi-modal data in the form of predictive models that support decision-making, Artificial Intelligence (AI) relies on a convergence of technologies with additional synergies with life science technologies. By enhancing our comprehension of disease heterogeneity, locating deregulated molecular pathways and therapeutic targets, designing and optimizing drug candidates, and evaluating *in silico* clinical efficacy, AI and machine learning enhance drug design and development. AI is fostering the emergence of computational precision medicine, which enables the design of therapies or preventative measures tailored to the singularities of individual patients in terms of their physiology, disease features, and exposure to environmental risks. This is made possible by providing an unprecedented level of knowledge on both the properties of drug candidates and patient specificities. A time and material saving method for powder characterization was developed in this study. Blends were selected in an effective manner to include the maximum variability of the underlying raw material dataset, building on an earlier developed raw material property database for use in the development of pharmaceutical dry powder processes. Powder characterization methods were minimized for blends and raw materials by selecting, using Principal Component Analysis (PCA), and the testing methods that described the greatest amount of variability in physical powder properties.

Conclusion

By determining the overarching properties outlined by the primary components of the PCA model, this method was chosen. From this dataset, the most distinguishing characterization methods for identifying differences in physical powder properties were identified as ring shear testing, powder bed compressibility, bulk/tapped density, helium pycnometry, loss on drying, and aeration. This guaranteed a responsibility decrease while the vast majority of the powder changeability that could be recognized was as yet included. This paper's method could be used as a material-saving alternative to the current "design of experiment" method. It will be further investigated to see if it can be used to speed up the development of new drug product formulations and processes and build an end-to-end predictive platform.